Interim study supports Vectorious LAP-guided patient self-management

Vectorious’ V-LAP, a left atrial pressure sensor (Image courtesy of Vectorious)

Vectorious Medical Technologies today announced interim results from a pilot study of its V-LAP sensor for heart failure management.

Tel Aviv, Israel-based Vectorious presented results from the left atrial pressure (LAP) guided patient self-management study at during an abstract session at THT 2023 in Boston.

The study has 13 enrolled patients to date. It includes New York Heart Association (NYHA) class II and III heart failure (HF) patients. These patients enrolled irrespective of left ventricular ejection fraction and received the V-LAP sensor in the left atrium.

Patients can see direct LAP readings captured by the sensor using a dedicated app and novel treatment paradigm. It allows self-management of diuretics and early intervention in cases of high LAP.

V-LAP allows patients to take a more active role in managing their disease. Using the system, patients can …

Read more
  • 0

Data backs splanchnic ablation procedure from Axon Therapies

The Satera ablation cathether. [Image courtesy of Axon Therapies]Axon Therapies today announced positive six-month results from a trial for its proprietary splanchnic ablation for volume management (SAVM) therapy.

Dr. Marat Fudim, advanced heart failure specialist at Duke University Medical Center, presented results at the Technology and Heart Failure Therapeutics (THT) Conference in Boston. The data came from a roll-in cohort for the REBALANCE-HF investigational device exemption feasibility trial.

Santa Clara, California-based Axon Therapies said its data remains consistent with prior results for the SAVM therapy. The novel, frontline therapy uses an outpatient ablation procedure. It aims to rebalance volume distribution for heart failure patients with preserved ejection fraction (HFpEF).

In addition to the positive results, Axon Therapies said it expects its trial to reach full enrollment by the end of the month. The approximately 120-patient study should…

Read more
  • 0

AccuCinch ventricular restoration system from Ancora Heart improves heart failure outcomes

The AccuCinch system. [Image courtesy of Ancora Heart]Ancora Heart announced today that its AccuCinch system demonstrated improvement in heart failure patient outcomes in an analysis.

Patients treated with the investigational device also saw beneficial changes in the structure of the heart. Twelve-month data were presented at the Technology and Heart Failure Therapeutics conference (THT 2023) and simultaneously published in the Journal of Cardiac Failure.

Dr. Nadira Hamid, an interventional echocardiographic and cardiologist at Allina Health Minneapolis Heart Institute and assistant director of the echocardiographic core lab at CRF, presented the data at the conference in Boston. Hamid also co-authored the corresponding manuscript, “Transcatheter Left Ventricular Restoration in Patients with Heart Failure.”

Data included complete 12-month clinical outcomes from an analysis of 51 symptomatic heart failure patients. These patients, treated with AccuCinch, had…

Read more
  • 0

Study says heart failure survival improves with Abbott CardioMEMS monitoring tech

Implanted in a catheter-based procedure, the CardioMEMS HF system remotely monitors pulmonary artery (PA) pressure changes to provide an early warning of worsening heart failure. [Image courtesy of Abbott]Abbott (NYSE:ABT) today announced new data supporting hemodynamic pressure sensing with its CardioMEMS HF system.

The data comes from an analysis evaluating CardioMEMS HF in heart failure patients with reduced ejection fraction (HFrEF). It aims to give doctors specific insight into how remote monitoring can provide early warnings for worsening heart failure. Abbott said it could demonstrate significantly reduced mortality risk (by 25%) at two years for HFrEF patients.

Abbott presented the meta-analysis of three randomized, controlled trials at the Technology and Heart Failure Therapeutics (THT) Conference in Boston. Data came from the Champion, Guide-HF and Laptop-HF trials. Abbott said it reinforces that remote monitoring technology, like CardioMEMS, can help do…

Read more
  • 0

Aortix circulatory support device from Procyrion produces positive study results

The Aortix pump therapy device. [Image courtesy of Procyrion]Procyrion today announced study results demonstrating that use of its Aortix device led to rapid decongestion in a pilot study.

Houston-based Procyrion evaluated Aortix percutaneous mechanical circulatory support (pMCS) pump in patients with acute decompensated heart failure (ADHF) and worsening renal function. This is known as cardiorenal syndrome (CRS).

The pump patients — unresponsive to available medical therapy — demonstrated significant improvements across a range of functions. These include kidney function, cardiac function and patient-reported assessment of shortness of breath at 30 days.

Procyrion presented results today at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Dr. Jennifer A. Cowger, section head of heart transplantation and mechanical circulatory support, Henry Ford Hospital in Detroit, said patients with CRS often end up the most difficult to …

Read more
  • 0

Study backs CVRx Barostim neuromod for patients with heart failure

CVRx’s Barostim Neo [Image courtesy of CVRx]Data presented today supported the use of the Barostim neuromodulation device from CVRx (Nasdaq:CVRX) in patients with cardiovascular diseases.

The BeAT-HF trial evaluated the Barostim extravascular, implantable neuromodulation device. Dr. Robert Zile, professor of cardiology at the Medical University of South Carolina, presented findings at the second annual Technology and Heart Failure (HF) Therapeutics (THT) conference in Boston.

Trial details

Zile said that the trial evaluated 323 randomized patients with a median follow-up of 3.6 years. The study of the FDA breakthrough device spanned 103 U.S. centers and five UK centers.

Findings included 97% freedom from major adverse neurological or cardiovascular (MANCE) system or procedure-related events. Long-term symptom improvement compared to control included a 44-meter improvement in a six-minute hall walk at 12 months. Quality of Life improved by 10 points on…

Read more
  • 0